Duloxetine

Generic Name: Duloxetine

Brand Names: Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉NOS

CAS Number: 116539-59-4

Unique Ingredient Identifier: O5TNM5N07U

Background: Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...

Indication: Indicated for:

1) Management of Major Depressive Disorder.

2) Management of Generalized Anxiety Disorder.

3) Management of diabetic peripheral neuropathy.

4) Management of fibromyalgia.

5) Management of chronic musculoskeletal pain.

6) Management of osteoarthritis of the knee in adults.

7) Management of chronic lower back pain in adults.
...

Associated Conditions: Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)

Associated Therapies: -

Clinical Trials

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

Phase 3

Completed

Conditions: Fibromyalgia

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 210

Registration Number: NCT00190866

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Portland, Oregon, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Fall River, Massachusetts, United States
🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)

Phase 3

Completed

Conditions: Urinary Incontinence, Stress

First Posted Date: 2005-09-19

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 500

Registration Number: NCT00190827

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Quebec, Canada
🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Barcelona, Spain

Duloxetine for the Treatment of Dysthymia

Not Applicable

Completed

Conditions: Depressive Disorder

First Posted Date: 2005-09-16

Last Posted Date: 2009-04-09

Lead Sponsor: Stanford University

Target Recruit Count: 24

Registration Number: NCT00185575

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

Phase 4

Completed

Conditions: Depression
Dementia

Interventions: Drug: Escitalopram
Drug: Donepezil
Drug: Placebo
Drug: Venlafaxine
Drug: Duloxetine

First Posted Date: 2005-09-15

Last Posted Date: 2013-02-06

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 220

Registration Number: NCT00177671

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Chronos: the Use of Chronobiological Treatment in Depression

Not Applicable

Completed

Conditions: Major Depression

Interventions: Procedure: Sleep deprivation
Behavioral: Exercise
Procedure: Light therapy
Procedure: Diurnal rhythms
Drug: duloxetine

First Posted Date: 2005-09-08

Last Posted Date: 2009-08-06

Lead Sponsor: Hillerod Hospital, Denmark

Target Recruit Count: 75

Registration Number: NCT00149110

Locations: 🇩🇰
Psychiatric Research Unit, Hilleroed Hospital, Hilleroed, Denmark

A Study of Duloxetine in the Treatment of Fibromyalgia

Phase 3

Completed

Conditions: Fibromyalgia

First Posted Date: 2005-08-02

Last Posted Date: 2007-05-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 320

Registration Number: NCT00125892

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours , EST ) or speak with your personal physician, Taipei, Taiwan
🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Morelia, Michoacan, Mexico
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your person physician, Taichung, Taiwan

and more 7 locations

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Anxiety Disorders

First Posted Date: 2005-07-22

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 480

Registration Number: NCT00122850

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seattle, Washington, United States

A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Anxiety Disorder

First Posted Date: 2005-07-22

Last Posted Date: 2007-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 560

Registration Number: NCT00122837

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Glasgow, Scotland, United Kingdom

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

Phase 3

Completed

Conditions: Anxiety Disorder

Interventions: Drug: Duloxetine
Drug: Placebo

First Posted Date: 2005-06-14

Last Posted Date: 2014-06-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT00114127

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Duloxetine
Drug: placebo

First Posted Date: 2005-03-21

Last Posted Date: 2009-07-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 514

Registration Number: NCT00105989

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sundsvall, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy